STOCK TITAN

Virpax Pharmaceuticals Inc - VRPX STOCK NEWS

Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.

Virpax Pharmaceuticals (VRPX) is advancing non-opioid pain management through innovative drug delivery systems, including metered-dose sprays and liposomal formulations. This news hub provides investors and industry observers with timely updates on preclinical developments, regulatory milestones, and strategic partnerships.

Our curated collection of VRPX news offers essential insights into the company's progress in developing alternatives to traditional pain therapies. Track updates across key areas including product pipeline advancements, intellectual property developments, and global research collaborations that shape the future of pain treatment.

Discover official press releases detailing Virpax's work on enkephalin-based therapies and hydrogel encapsulation technologies. Stay informed about critical updates through verified financial disclosures and scientific progress reports, all maintained in one centralized location for efficient research.

Bookmark this page for ongoing access to VRPX's latest achievements in pharmaceutical innovation. Check regularly for new developments in their mission to enhance therapeutic outcomes while reducing opioid dependency risks.

Rhea-AI Summary
Virpax Pharmaceuticals expects to submit an Investigational New Drug Application (IND) for Envelta in mid-2024, allowing clinical trials to begin. Envelta is a non-addictive pain product candidate for acute and chronic pain. It utilizes a novel intranasal drug delivery system called Molecular Envelope Technology (MET) to bypass the blood-brain barrier. Preclinical studies in rats and dogs have shown positive efficacy with minimal adverse effects. Virpax plans to advance Envelta through preclinical development and conduct first-in-human trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals extends CRADA with U.S. Army Institute of Surgical Research for Probudur
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
-
Rhea-AI Summary
Gerald W. Bruce appointed as President and CEO of Novvae Pharmaceuticals, Virpax's subsidiary focused on OTC pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
Rhea-AI Summary
Virpax Pharmaceuticals announces positive results for two pre-clinical Probudur dose escalation studies, showing three times longer efficacy than Exparel in the first study and four to five times longer effect in the second study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals will be presenting at the 16th annual Main Event on Tuesday, October 3rd at 12:00 PM PT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
Rhea-AI Summary
Altasciences chosen by Virpax Pharmaceuticals to conduct preclinical studies for their nanoparticle AnQlar™, which aims to prevent the spread of COVID-19 and influenza. Positive collaboration and progress reported by both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
Rhea-AI Summary
Virpax Pharmaceuticals forms subsidiary Novvae to focus on OTC pipeline, while Virpax focuses on Rx product pipeline. Novvae's first asset, AnQlar, demonstrated 24-hour anti-viral barrier activity against Influenza and Covid. Virpax in discussions for global rights of first refusal on two non-prescription assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals announces ruling on lawsuit filed by Scilex Pharmaceuticals and Sorrento Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. to present at H.C. Wainwright event, CEO giving presentation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) announced its financial results for Q2 2023. The company reported a decrease in general and administrative expenses and research and development expenses compared to the same period last year. The operating loss for Q2 2023 was $3.2 million. As of June 30, 2023, the company had $14.8 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
Virpax Pharmaceuticals Inc

Nasdaq:VRPX

VRPX Rankings

VRPX Stock Data

198.80k
1.27M
1.13%
0.47%
3.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERWYN